Stockpiled Ventilators That Can't Ventilate

The COVID-19 pandemic revealed that many ventilators stockpiled in the Strategic National Stockpile and procured under emergency contracts had capabilities "far below standards" for critical care ventilation, lacking features essential for ARDS management such as high PEEP, precise tidal volume control, and advanced monitoring. The FDA's Emergency Use Authorization process authorized devices with widely varying performance capabilities under a single "ventilator" classification, making it impossible for clinicians to distinguish devices suitable for critical care from those appropriate only for basic respiratory support. No binding performance tier standard exists that differentiates critical care ventilators from transport, home-use, or emergency ventilators by clinical capability, and this gap remains unaddressed for future emergencies.

In a future respiratory pandemic or mass casualty event, the capability gap between stockpiled devices and clinical needs could directly contribute to preventable deaths on a massive scale. The United States maintains approximately 170,000 full-featured ventilators, but severe pandemic modeling projected a need for 300,000+ critical care ventilators — a shortfall that would affect tens of thousands of patients. During COVID-19, ventilator shortages led to crisis standards of care, rationing, and use of suboptimal devices, with clinicians forced to repurpose anesthesia machines and home-use CPAP/BiPAP devices that were never designed for the ventilatory strategies required by severe ARDS.

The FDA recognizes multiple ventilator categories (critical care, transport, home use) but there is no mandatory performance standard defining minimum capabilities for each tier — no required minimum PEEP range, tidal volume accuracy, FiO2 control, or ventilation modes. ISO 80601-2-12 provides performance requirements for critical care ventilators, but compliance is not mandatory for all FDA-cleared devices marketed as "ventilators." During the pandemic, the FDA issued EUAs that authorized a wide range of devices — modified anesthesia gas machines, home CPAP/BiPAP devices, and emergency transport ventilators — all under the same general authorization without performance tier differentiation. The failed Philips/BARDA stockpile contract exemplified the deeper structural issue: pre-pandemic procurement optimized for cost and quantity rather than clinical capability, producing devices that were cheap to stockpile but inadequate for the patients who needed them. Post-pandemic, the EUA pathway has been wound down for ventilators, but political salience of pandemic preparedness has declined, reducing momentum for the regulatory reform needed to prevent the same failure next time.

A binding, tiered performance standard — adopted by FDA and referenced by BARDA procurement specifications — that clearly defines minimum clinical capabilities for each ventilator category would ensure stockpiled devices can actually perform the clinical functions required in a crisis. This standard should be paired with procurement specifications that weight clinical capability alongside cost-per-unit, changing the incentive structure that produced the current stockpile gap. Modular ventilator designs that allow capability upgrades (adding modes, monitoring, or precision controls to a base platform) could bridge the cost-capability tradeoff.

A student team could conduct a systematic comparison of currently stockpiled ventilator models against published clinical requirements for ARDS management, producing a gap analysis and proposed performance tier framework. An engineering team could prototype a modular ventilator architecture where a low-cost base unit can be upgraded with snap-in modules for advanced modes (pressure-regulated volume control, high PEEP capability, waveform monitoring) to address the cost-versus-capability tradeoff. A policy-focused team could draft a model procurement specification for state or federal emergency ventilator stockpiles that incorporates clinical capability tiers.